Table 2.

Inflammatory biomarkers before and after percutaneous transluminal angioplasty

Biomarkers	Control, n=17	PTA, n=56
		Patent, n=33	Restenosis, n=23	P Value
Absolute level
hs-CRP, mg/L
Before	0.22 (0.12–0.61)	0.54 (0.21–1.10)	0.34 (0.23–0.76)	0.32
2 d	0.29 (0.10–0.49)	0.59 (0.29–1.40)	0.56 (0.36–0.86)	0.99
2 wk	0.22 (0.10–0.66)	0.60 (0.19–1.35)	0.39 (0.23–0.98)	0.46
3 mo	0.36 (0.11–0.62)	0.43 (0.18–1.24)	0.52 (0.25–0.72)	0.66
MCP-1, pg/ml
Before	425 (379–493)	362 (268–425)	303 (248–375)	0.09
2 d	442 (378–484)	427 (310–505)	437 (386–792)	0.54
2 wk	416 (368–510)	389 (255–432)	361 (300–446)	0.37
3 mo	381 (351–503)	356 (255–432)	321 (258–394)	0.50
IL-6, pg/ml
Before	4.9 (2.9–9.7)	5.0 (3.0–8.3)	3.6 (2.6–11.3)	0.73
2 d	5.5 (2.7–8.6)	5.0 (2.9–8.8)	6.1 (2.9–13.8)	0.56
2 wk	5.5 (3.2–7.1)	5.5 (3.2–10.7)	5.4 (3.0–16.4)	0.70
3 mo	4.7 (2.4–9.7)	4.8 (3.1–6.9)	3.9 (2.6–12.7)	0.71
Percentage change
hs-CRP, %
2 d	−7 (−31–52)	8 (−18–128)	41 (−13–89)	0.31
2 wk	−4 (−38–56)	14 (−37–138)	9 (−3–31)	0.99
3 mo	−22 (−32–78)	−45 (−61–42)	8 (−24–82)	0.07
MCP-1, %
2 d	−2 (−6–7)	17 (10–25)	47 (27–60)	<0.001
2 wk	−6 (−11–7)	11 (−1–22)	21 (9–36)	0.05
3 mo	−6 (−11–5)	−1 (−4–5)	6 (1–13)	0.10
IL-6, %
2 d	−10 (−23–19)	19 (−41–69)	32 (−12–97)	0.26
2 wk	−10 (−22–18)	4 (−25–98)	42 (4–82)	0.29
3 mo	7 (−16–14)	−4 (−14–14)	11 (−23–63)	0.33

Values are expressed as medians (interquartile ranges); P values are patent versus restenosis. PTA, percutaneous transluminal angioplasty; hs-CRP, high–sensitivity C–reactive protein; MCP-1, monocyte chemoattractant protein-1.